Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azimilide (Procter & Gamble).

P Light1

  • 1Department of Pharmacology, University of Alberta, 9-58 Medical Sciences, Edmonton, AB T6G 2H7, Canada. peter.light@ualberta.ca

Idrugs : the Investigational Drugs Journal
|July 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sitagliptin plus pantoprazole can restore but not maintain insulin independence after clinical islet transplantation: results of a pilot study.

Diabetic medicine : a journal of the British Diabetic Association·2016
Same author

Electromagnetically-induced transparency grid in acetylene-filled hollow-core PCF.

Optics express·2009
Same author

Nesiritide citrate (Scios).

IDrugs : the investigational drugs journal·2005
Same author

Pamicogrel (Kanebo).

IDrugs : the investigational drugs journal·2005
Same author

Vancomycin-resistant enterococci colonization in patients at seven hemodialysis centers.

Kidney international·2001
Same author

A prospective study of vascular access infections at seven outpatient hemodialysis centers.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2001
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Azimilide, an anti-arrhythmic drug, prolonged the arrhythmia-free period in patients with atrial fibrillation. Further studies are evaluating its safety and efficacy in post-heart attack patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Science

Background:

  • Azimilide is a class III anti-arrhythmic agent developed for maintaining sinus rhythm.
  • It has been investigated for supraventricular arrhythmias and in patients with implantable cardioverter defibrillators (ICDs).

Purpose of the Study:

  • To evaluate azimilide's efficacy in prolonging the arrhythmia-free period in patients with atrial fibrillation.
  • To assess the safety and efficacy of azimilide in patients post-myocardial infarction.

Main Methods:

  • Pivotal clinical trials and Phase III studies, including the Azimilide Supraventricular Arrhythmia Program Trial (ASAP).
  • The ongoing Azimilide Post-Infarct Survival Evaluation (ALIVE) multicenter trial involves 6000 post-heart attack patients.

Related Experiment Videos

Main Results:

  • Azimilide significantly prolonged the arrhythmia-free period in patients with atrial fibrillation.
  • Three deaths occurred in the azimilide group versus one in the placebo group in the ASAP trial.

Conclusions:

  • Azimilide demonstrates potential in managing atrial fibrillation by extending arrhythmia-free intervals.
  • Ongoing trials will further define its role in cardiovascular disease management, particularly post-myocardial infarction.